Newsroom

Sorted by: Latest

-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust NASDAQ Clean Edge Green Energy UCITS ETF 01.04.2026 QCLN.LN IE00BDBRT036 975,002.00 USD 17,525,930.62 17.975  ...
-

Hartree Partners Completes Acquisition of Touton SAS

NEW YORK & BORDEAUX--(BUSINESS WIRE)--Hartree Partners, LP (“Hartree”), a global energy and commodities trading firm, and Touton SAS ("Touton"), a leading independent soft commodity trading company, today announced the completion of Hartree's acquisition of Touton, following consultation with employees' representatives and satisfaction of all customary closing conditions. The transaction extends Hartree's strategic growth in commodities, building on its July 2025 acquisition of ED&F Man Com...
-

Hartree Partners finalise l'acquisition de Touton SAS

NEW YORK & BORDEAUX--(BUSINESS WIRE)--Hartree Partners, LP (« Hartree »), groupe mondial de négoce d’énergie et de commodités, et Touton SAS (« Touton »), spécialiste du négoce de matières premières agricoles, annoncent aujourd'hui la finalisation de l'acquisition de Touton par Hartree, à l'issue de la consultation des représentants du personnel et après satisfaction de l'ensemble des conditions suspensives. Avec cette opération, Hartree poursuit sa stratégie de croissance dans le secteur des m...
-

Clarametyx Biosciences Strengthens Executive Leadership to Accelerate Clinical Development Efforts

COLUMBUS, Ohio--(BUSINESS WIRE)--Clarametyx announced that Veronica Hall, PhD, has been promoted to CDO and Head of R&D and Brendan Doran, PharmD, has been promoted to COO....
-

Soluna Closes $53M Briscoe Wind Farm Acquisition; Achieves Vertical Integration

ALBANY, N.Y.--(BUSINESS WIRE)--Soluna Holdings, Inc. (“Soluna” or the “Company”) (NASDAQ: SLNH), a developer of green data centers that converts renewable energy into computing power, today announced that it has closed the acquisition of the 150 MW Briscoe Wind Farm in West Texas for a total purchase price of $53.0 million. The transaction was financed through cash on the balance sheet and debt. The acquisition is expected to be immediately accretive, with projected Year-One Adjusted EBITDA of...
-

Lincoln Electric Schedules Webcast for First Quarter 2026 Results

CLEVELAND--(BUSINESS WIRE)--Lincoln Electric schedules its first quarter 2026 earnings call for Thursday, April 30, 2026 at 10:00am (ET)....
-

Realbotix Closes Sale of Domain Name Portfolio for US$2.245

LAS VEGAS--(BUSINESS WIRE)--Realbotix Corp. (TSX-V: XBOT) (Frankfurt: 76M0.F) (OTC: XBOTF) (“Realbotix” or the “Company”), a leading human-centric AI and humanoid robot manufacturer, today announced that it has successfully closed the previously announced sale of the Tokens.com domain portfolio to Bed Bath & Beyond, Inc. for total consideration of US$2.245 million. The transaction represents the monetization of non-core digital assets and does not involve the transfer of any operating busin...
-

Armatus Announces Groundbreaking Data Supporting TVR110, a Vectorized MicroRNA Therapy for the Treatment of Charcot-Marie-Tooth Disease Type 1A

COLUMBUS, Ohio--(BUSINESS WIRE)--Armatus has published data in Molecular Therapy Nucleic Acids describing TVR110, a first-in-class vectorized microRNA for CMT1A....
-

Triple Hair administre la première dose au premier patient dans le cadre de son essai clinique de phase III au Canada pour l’alopécie androgénique masculine

MONTRÉAL--(BUSINESS WIRE)--Triple Hair Group Inc. (« Triple Hair » ou la « Société »), une société spécialisée dans le développement de traitements novateurs contre l'alopécie androgénique (calvitie), a annoncé aujourd’hui que le premier patient a été dosé dans le cadre de son essai clinique de phase III au Canada visant à évaluer TH07, le traitement topique sur ordonnance breveté de la Société contre la calvitie. L’essai clinique de phase III (NCT07435012) est conçu pour évaluer l’innocuité et...
-

Triple Hair Doses First Patient in Phase III Clinical Trial in Canada for Male Androgenic Alopecia

MONTRÉAL--(BUSINESS WIRE)--Triple Hair Group Inc. (“Triple Hair” or the “Company”), a company specializing in the development of innovative treatments for androgenic alopecia (pattern baldness), today announced that the first patient has been dosed in its Phase III clinical trial in Canada evaluating TH07, the Company’s patented prescription topical treatment for male pattern hair loss. The Phase III clinical trial (NCT07435012) is designed to evaluate the safety and efficacy of TH07 in men wit...